Abstract
The immunosuppressive tumor microenvironment (TME) is a major obstacle in cancer immunotherapy. Therefore, it has gained attention as a target site. mRNA emerged as a versatile drug class for cancer therapy. We reported that intratumoral administration of mRNA encoding the fusokine Fβ(2) supports tumor-specific T-cell immunity. This study provides proof of concept of the use of mRNA to modulate the TME.